IOVA Q1 2023 Earnings — Iovance Biotherapeutics, Inc. Revenue & Financial Results | Market Cap Arena

IOVAIovance Biotherapeutics, Inc.

$2B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$111M

Net Income

-$107M

EPS (Diluted)

$-0.50

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$100M

Free Cash Flow

-$105M

Stock-Based Comp.

$16M

Balance Sheet

Total Assets

$825M

Total Liabilities

$158M

Stockholders' Equity

$667M

Cash & Equivalents

$543M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$111M	-$92M	-20.9%
Net Income	-$107M	-$92M	-17.2%